Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028

2019-12-31
Price :
Published : Dec-2019
No. of Pages : 38

Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028

Summary

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disease characterized by coughing that produces large amounts of mucus, difficulty in breathing, shortness of breath (initially with exertion), wheezing, chest tightness, and other respiratory symptoms. The disease is diagnosed based on symptoms and the results of spirometry testing, which measures how deeply a person breathes and how fast air moves in and out of the lungs (World Health Organization, 2017). Spirometry results can also be used to determine the severity of COPD. The most commonly used severity criteria is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) standard.

GlobalData epidemiologists utilized county-specific studies published in peer-reviewed journals as well as medical record review studies to build the forecast. The disease definition for COPD was based on symptoms and the results of spirometry testing. The report includes a 10-year epidemiological forecast for the total prevalent and diagnosed prevalent cases of COPD in the 7MM. GlobalData epidemiologists followed the GOLD 2011 and GOLD 2016 criteria for the severity stages of COPD in this forecast across the 7MM.

The following data describes epidemiology of COPD. In the 7MM, GlobalData epidemiologists forecast an increase in the total prevalent cases of COPD from 59,286,188 cases in 2018 to 67,185,113 cases in 2028 at an AGR of 1.33% during the forecast period. In the 7MM, the diagnosed prevalent cases of COPD will increase from 30,733,034 cases in 2018 to 34,561,468 cases in 2028 at an AGR of 1.25% during the forecast period. COPD is more common in older adults. These trends are reflected in GlobalData’s forecast for the total prevalent cases, and diagnosed prevalent cases for the 7MM.

Scope

– The Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Report provides an overview of the risk factors and global trends of COPD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
– The report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of COPD segmented by sex, and age (ages ?35 years) in these markets. The diagnosed prevalent cases of COPD are further segmented by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 as well as GOLD 2016 severity stage (GOLD A, GOLD B, GOLD C, and GOLD D) using the COPD Assessment Test (CAT) scores and the modified Medical Research Council (mMRC) dyspnea scores.
– The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
– The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Chronic Obstructive Pulmonary Disease Epidemiology series will allow you to –
– Develop business strategies by understanding the trends shaping and driving the global COPD market.
– Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.
– Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for COPD therapeutics in each of the markets covered.
– Understand magnitude of COPD population by severity at diagnosis.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

US Therapeutic Plasma Exchange Market by Product (Devices, Consumables) Technology (Centrifugation, Membrane Separation) Procedures & Patients (Guillain Syndrome, Multiple Sclerosis, Cryoglobulinemia) End Users Covid-19 Impact – Forecast to 2025

 “The US therapeutic plasma exchange market is projected to grow at a CAGR of 6.3%.” The US therapeutic plasma exchange market is projected to reach USD 243 million by 2025 from USD 178 million in 2020, at a CAGR of 6.3% during the forecast period. Growth in this market is driven by the rising prevalence of chronic diseases and technological advancements. However, factors such as the high cost of apheresis devices and therapeutic plasma exchange procedures and installation of apheresis devices through a rental model are expected to restrain the growth of this market to a certain extent during the forecast period. “The consumables segment to grow at the highest rate during the forecast period.” On the basis of products, the US therapeutic plasma exchange market has been s......
$4950

Pharmaceutical Trade and Supply Chain Survey, Q3 2020 – Coronavirus Disease 2019 (COVID-19) Impact

Pharmaceutical Trade and Supply Chain Survey, Q3 2020 - Coronavirus Disease 2019 (COVID-19) Impact Summary This report provides an update on the assessment of how the pharmaceutical industry perceives the supply chain disruption caused by the COVID-19 pandemic, including the challenges associated with clinical trials, logistics, API and finished dose manufacturing. Since the first case was diagnosed in Wuhan, China, in December 2019, COVID-19 cases have continued to rise rapidly across the globe. Scope - Report provides in-house analyst expertise on the results of a 5 minute survey of 75 GlobalData Pharma clients and prospects, which was fielded from July 7, 2020 to July 30, 2020. Reasons to Buy Objectives included - - Benchmark companies' primary concerns - Determine the impact of......
$1495

Coronavirus Disease 2019 (COVID-19) Case Study – A Look at Increased Cybersecurity Risk Across the Healthcare Industry

Coronavirus Disease 2019 (COVID-19) Case Study - A Look at Increased Cybersecurity Risk Across the Healthcare Industry Summary The COVID-19 pandemic has increased cyber risk significantly, with certain situations being exploited by malicious actors during the crisis. This includes a rush to utilize remote working with little time to plan or train employees, a high demand for personal protective equipment (PPE), lockdown measures, reduced mobility, and increased fear and anxiety among the public. This case study contains a review of the rise in cyber attacks on the healthcare industry seen during the COVID-19 pandemic, with examples of attacks on biopharmaceutical and research companies, hospitals, payers, and other healthcare providers. Key Highlights - Hospitals and healthcare provide......
$595

Amyotrophic Lateral Sclerosis (ALS) – Opportunity Analysis and Forecasts to 2029

Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2029 Summary Amyotrophic Lateral Sclerosis (ALS) is a motor neuron degenerative disease which affects both upper motor neurons (UMN) and lower motor neurons (LMN). It is a progressive disease, with patients becoming increasingly dependent on carers and physicians as time from onset increases, and ultimately, it is fatal. ALS can be split into two origins, hereditary - which is known as FALS (Familial ALS) or idiopathic - known as SALS (sporadic ALS). ALS current treatment includes only two disease-modifying drugs: Sanofi's Rilutek (riluzole) and Mitsubishi Tanabe's Radicava/Radicut (edaravone). Two reformulations of riluzole were approved recently: ITF Pharma's Tiglutik (riluzole oral suspension) in 2018 and Aq......
$10995

Amyotrophic Lateral Sclerosis – Epidemiology Forecast to 2029

Amyotrophic Lateral Sclerosis - Epidemiology Forecast to 2029 Summary Amyotrophic lateral sclerosis (ALS) is a group of rare but fatal neurodegenerative diseases that primarily involve the nerve cells (neurons) in the brain and spinal cord responsible for controlling voluntary muscle movement like chewing, walking, and talking (National Institute of Neurological Disorders and Stroke, 2020). ALS is often called Lou Gehrig's disease, after the baseball player who was diagnosed with the disease in 1939 (Mayo Clinic, 2019). Most people with ALS die from respiratory failure, usually within three to five years from when the symptoms first appear. Currently, there is no cure for ALS and no effective treatment to stop, or reverse, the progression of the disease (National Institute of Neurologica......
$3995

Gastric and Gastroesophageal Junction Adenocarcinoma – Epidemiology Forecast to 2029

Gastric and Gastroesophageal Junction Adenocarcinoma - Epidemiology Forecast to 2029 Summary Gastric cancer, also known as stomach cancer, occurs when cancer cells form in the lining of the stomach. Approximately 90% to 95% of gastric cancer cases are considered to be an adenocarcinoma, a cancer that develops in the mucosa—the innermost layer of the stomach. Gastric cancer usually develops slowly and rarely shows any signs or symptoms in the early stages. The majority of gastric cancer cases are diagnosed at an advanced stage. Symptoms of gastric cancer can include poor appetite, weight loss, abdominal pain, nausea, blood in the stool, and vomiting. GlobalData epidemiologists used age- and sex-specific diagnosed incidence rates to forecast the diagnosed incident cases, and used the obs......
$3995

Crohn’s Disease – Epidemiology Forecast to 2029

Crohn's Disease - Epidemiology Forecast to 2029 Summary Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. It most commonly affects the end of the small intestine (the ileum) where it joins the beginning of the colon. Crohn's disease may appear in "patches," affecting some areas of the gastrointestinal tract while leaving other sections completely untouched. (Crohn's and Colitis Foundation of America, 2014). Men and women can both be affected and the disease can occur at any age, but CD is more prevalent among women and in the young age population. Diet and stress may aggravate CD, but do not cause the disease. (Crohn's and Colitis UK, 2018; Crohn's and Colitis Foundation, 2020a). GlobalData epidemiologists ut......
$3995

Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology, Pulmonology), End User (Hospitals & Clinics) – Global Forecast to 2025

 “Growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the growing prevalence of respiratory diseases and alpha-1-antitrypsin deficiency (AATD) is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 39.5 billion by 2025 from USD 28.6 billion in 2020, at a CAGR of 6.7% during the forecast period. Growth in the plasma fractionation market is primarily driven by factors such as growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), rising geriatric population, and the growing prevalence of respiratory diseases and alpha-1-ant......
$4950

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (Practice Management, e-Prescribing, PHM, Health Analytics, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User – Global Forecast to 2025

“Government support to increase adoption of EHR solutions is expected to drive the overall growth of the ambulatory EHR market.” The ambulatory EHR market is expected to reach USD 6.8 billion by 2025 from USD 5.2 billion in 2020, at a CAGR of 5.7% during the forecast period of 2020 to 2025. Growth in the global ambulatory EHR market can primarily be attributed to various factors such as government support for the adoption of EHR solutions, increasing number of outpatient care centers, growing patient volume due to the global outbreak of COVID-19, and the need to curtail healthcare costs. On the other hand, market growth is limited to a certain extent due to factors such as reluctance to adopt EHR solutions in developing countries, heavy infrastructure investments, and the high cost ......
$4950

Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020

Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020 Summary GlobalData's clinical trial report, "Nasopharyngeal Cancer Global Clinical Trials Review, H2, 2020" provides an overview of Nasopharyngeal Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Nasopharyngeal Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma - Clinica......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy